NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
Clinical Trials
3 trialsNCT07375563 2026-01-29
NB-NK-2026
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT06071897 2023-10-10
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting